Press release from Companies
Published: 2025-06-19 16:30:00
On 23 May 2025, PEPTONIC medical AB ("Peptonic" or the "Company") issued a notice to the annual general meeting to be held on 26 June 2025. The notice to the annual general meeting proposed that the board of directors should consist of four (4) ordinary board members without deputies and that the nomination committee intended to present proposals for board members as soon as possible. In light of this, the Company is publishing the nomination committee's proposals for board members.
Item 11 - Election of board members and any deputy board members
The nomination committee proposes that Anders Blom, Jacob Eriksson, Daniel Rudeklint, and Tarek Shoeb, be re-elected as board members for the period until the end of the next annual general meeting. Anders Blom is proposed for re-election as chairman of the board.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
